SELLAS Life Sciences Group, Inc. (SLS)
- Previous Close
1.5200 - Open
1.5300 - Bid 1.4700 x 100
- Ask 1.4800 x 100
- Day's Range
1.4700 - 1.5450 - 52 Week Range
0.5000 - 1.9100 - Volume
499,599 - Avg. Volume
1,473,869 - Market Cap (intraday)
82.714M - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.83
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
www.sellaslifesciences.comRecent News: SLS
Performance Overview: SLS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLS
Valuation Measures
Market Cap
85.53M
Enterprise Value
83.90M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.22
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-174.27%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-37.34M
Diluted EPS (ttm)
-1.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
2.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-29.64M